|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||117.33 - 121.20|
|52 Week Range||63.41 - 142.11|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||56.72|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||155.71|
In this article we are going to estimate the intrinsic value of Haemonetics Corporation ( NYSE:HAE ) by projecting its...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $425,000,000 aggregate principal amount of notes. The offering is expected to close on March 5, 2021, subject to customary closing conditions. Haemonetics also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $65,000,000 principal amount of notes.